RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Luye Pharma Group Stock

Luye Pharma Group ROE 2024

Luye Pharma Group ROE

0.04

Ticker

2186.HK

ISIN

BMG570071099

WKN

A116Z9

In 2024, Luye Pharma Group's return on equity (ROE) was 0.04, a -28.49% increase from the 0.06 ROE in the previous year.

Luye Pharma Group Aktienanalyse

What does Luye Pharma Group do?

The Luye Pharma Group Ltd is a leading company in the pharmaceutical industry that offers a wide range of high-quality therapeutics and healthcare products to its customers. The company was founded in 1994 and is headquartered in Yantai, China. The history of the Luye Pharma Group Ltd dates back to 1994 when it was established as a small research and development unit. Since then, the company has grown into a global corporation operating in over 80 countries. In recent years, the Luye Pharma Group Ltd has expanded its drug manufacturing through the integration of CDMO Services and has also been involved in many mergers and acquisitions. The business model of the Luye Pharma Group Ltd is based on a wide product portfolio that encompasses research and development as well as manufacturing. The company has a strong product portfolio in the areas of neurology, oncology, cardiometabolic diseases, and sleep medicine. Its various business units work on the development, production, and marketing of innovative medications and healthcare products. The Luye Pharma Group Ltd is divided into several divisions specialized in meeting the requirements and needs of different customers: 1. Neurology: This division focuses on the research and development of medications for the treatment of neurological disorders and psychiatric conditions. The company offers a variety of products for epilepsy, Alzheimer's disease, Parkinson's disease, and depression. 2. Oncology: This division develops and manufactures drugs for the treatment of cancer. The company has a range of products for breast cancer, bladder cancer, prostate cancer, and lung cancer. 3. Cardiometabolic Diseases: This division offers a product range that includes medications for the treatment of diabetes and hypertension, as well as for the prevention and treatment of cardiovascular diseases. 4. Sleep Medicine: This division provides a wide portfolio of sleep and sedative medications without the well-known side effects such as sedation or respiratory problems. The company is also focusing on technologies such as nanoparticles, probiotics, and new delivery forms to further enhance the category of medications. Luye Pharma Group Ltd offers a wide range of high-quality medications and healthcare products. Some of its well-known products include Seroquel XR for the treatment of depression and bipolar disorders, Lipusuap for the treatment of breast cancer, Zuclopenthoxil hydrochloride for the treatment of schizophrenia, Cozaar for the treatment of hypertension, Risperidone for the treatment of psychotic disorders, and Yitian as a natural sleep aid. In summary, the Luye Pharma Group Ltd is a leading manufacturer of medications and healthcare products with a wide product range ranging from neurology to oncology and sleep and sedative therapeutics. The company is headquartered in Yantai, China, and is represented in over 80 countries. The Luye Group has strengthened its position in the global market through numerous acquisitions in recent years. Luye Pharma Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Luye Pharma Group's Return on Equity (ROE)

Luye Pharma Group's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Luye Pharma Group's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Luye Pharma Group's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Luye Pharma Group’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Luye Pharma Group stock

What is the ROE (Return on Equity) of Luye Pharma Group this year?

The ROE of Luye Pharma Group this year is 0.04 undefined.

How has the Return on Equity (ROE) of Luye Pharma Group developed compared to the previous year?

The ROE of Luye Pharma Group has increased by -28.49% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Luye Pharma Group?

A high ROE indicates that Luye Pharma Group generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Luye Pharma Group?

A low ROE can indicate that Luye Pharma Group is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Luye Pharma Group affect the company?

A change in ROE (Return on Equity) of Luye Pharma Group can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Luye Pharma Group?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Luye Pharma Group?

Some factors that can influence Luye Pharma Group's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Luye Pharma Group pay?

Over the past 12 months, Luye Pharma Group paid a dividend of 0.06 CNY . This corresponds to a dividend yield of about 2.16 %. For the coming 12 months, Luye Pharma Group is expected to pay a dividend of 0 CNY.

What is the dividend yield of Luye Pharma Group?

The current dividend yield of Luye Pharma Group is 2.16 %.

When does Luye Pharma Group pay dividends?

Luye Pharma Group pays a quarterly dividend. This is distributed in the months of October, July, October, July.

How secure is the dividend of Luye Pharma Group?

Luye Pharma Group paid dividends every year for the past 3 years.

What is the dividend of Luye Pharma Group?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Luye Pharma Group located?

Luye Pharma Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Luye Pharma Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Luye Pharma Group from 7/24/2020 amounting to 0.06 CNY, you needed to have the stock in your portfolio before the ex-date on 6/29/2020.

When did Luye Pharma Group pay the last dividend?

The last dividend was paid out on 7/24/2020.

What was the dividend of Luye Pharma Group in the year 2023?

In the year 2023, Luye Pharma Group distributed 0 CNY as dividends.

In which currency does Luye Pharma Group pay out the dividend?

The dividends of Luye Pharma Group are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Luye Pharma Group

Our stock analysis for Luye Pharma Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Luye Pharma Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.